POSA58 Cost-Effectiveness (CE) Analyses for First-Line (1L) Treatment of Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.203
https://www.valueinhealthjournal.com/article/S1098-3015(21)01998-7/fulltext
Title :
POSA58 Cost-Effectiveness (CE) Analyses for First-Line (1L) Treatment of Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01998-7&doi=10.1016/j.jval.2021.11.203
First page :
Section Title :
Open access? :
No
Section Order :
10972